Fierce Pharma

NOVEMBER 6, 2024

Drugs for unmet needs and those from experienced companies had the best chance for successful launches in 2023: report kdunleavy Wed, 11/06/2024 - 09:23

289

289

Fierce Pharma

OCTOBER 2, 2023

After laying out a goal to launch four new drugs in 2023, Eli Lilly has run into yet another regulatory snag. | The FDA has rejected Lilly’s investigational atopic dermatitis treatment lebrikizumab over findings uncovered during the inspection of a third-party contract manufacturing organization.

FDA 296

FDA Manufacturing 296

Fierce Pharma

DECEMBER 20, 2023

Following an IPO and ahead of its fiscal 2023 earnings release next month, German drug containment and delivery specialist Schott Pharma is trumpeting its recent momentum. | Following an IPO and ahead of its fiscal 2023 earnings release next month, pharma glass specialist Schott Pharma is trumpeting its recent momentum.

Pharma 262

Pharma Sales 262

Fierce Pharma

NOVEMBER 6, 2023

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to a | BioNTech has slashed its estimate of 2023 revenue by 20%, now expecting it to reach 4 billion euros ($4.3

Sales 286

Sales 286

Fierce Pharma

FEBRUARY 7, 2024

With the previous year in the rearview and exciting developments already in the mix for 2024, Novo Nordisk’s CEO is taking home a cool 13% raise for his performance in 2023.

246

246

Fierce Pharma

DECEMBER 22, 2023

Even with the Federal Trade Commission keeping a watchful eye on the biopharma industry and the economic landscape giving some players pause, mergers and acquisitions are back on the rise.

Biopharma 350

Biopharma 350

Fierce Pharma

JANUARY 9, 2024

Pfizer knows it had a bad year in 2023. Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Speaking to reporters at the 2024 J.P.

Healthcare 349

Healthcare Healthcare 349

Fierce Pharma

FEBRUARY 8, 2024

billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014.

321

321

Fierce Pharma

MARCH 20, 2024

Four months ago, when BioNTech slashed its 2023 revenue projection from 5 billi | When BioNTech reported its fourth-quarter earnings Wednesday, it was another harsh reminder of the plummeting demand for COVID-19 vaccines. billion) for 2023, coming up short of expectations. Sales came to 1.5 billion euros ($1.6 billion euros ($4.1

Sales 336

Sales 336

Fierce Pharma

JUNE 12, 2024

As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target | As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has (..)

Pharma 344

Pharma 344

Fierce Pharma

JANUARY 25, 2024

Last year proved a challenging year for contract manufacturers across the board, but Korea’s Samsung Biologics appears to have bucked the losing trend by charting what it called an “exceptional" pe | Last year proved a challenging year for contract manufacturers across the board, but Korea’s Samsung Biologics appears to have bucked the losing (..)

Manufacturing 262

Manufacturing 262

Fierce Pharma

APRIL 5, 2024

million in 2023, which was an increase of 30% from her $15.9 Vertex CEO Reshma Kewalramani, M.D., million pay in 2022.

355

355

Fierce Pharma

MARCH 25, 2024

In 2023, Eli Lilly CEO David Ricks received a 24% boost in pay from $21.4 million to $26.6 The increase coincides with the company's booming sales.

Sales 359

Sales 359

Fierce Pharma

OCTOBER 11, 2023

Fierce Pharma sits down with digital marketing leaders to discuss this year's most innovative topics at Digital Pharma East. Learn more by watching the videos below. Fierce Pharma sits down with digital marketing leaders to discuss this year's most innovative topics at Digital Pharma East.

Pharma 246

Pharma Marketing 246

Fierce Pharma

AUGUST 30, 2023

After a tumultuous year of manufacturing hiccups, executive turnover and dwindling revenues, Catalent is handing the reins to activist investor Elliott Management. After a tumultuous year of manufacturing hiccups, executive turnover and dwindling revenues, Catalent is linking up with Elliott Management.

Government 290

Government Manufacturing Management 290

Fierce Pharma

AUGUST 7, 2024

As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal has taken home the gold in the U.S.

FDA 283

FDA Marketing 283

Fierce Pharma

OCTOBER 13, 2023

The popular diabetes med Ozempic and its sister weight-loss drug Wegovy are boosting Novo Nordisk to new highs again and again. | The popular diabetes med Ozempic and its sister weight-loss drug Wegovy are boosting Novo Nordisk to new highs again and again.

Sales 311

Sales 311

Fierce Pharma

MAY 26, 2023

Johnson & Johnson cites rebates and discounts for drug price increases kdunleavy Fri, 05/26/2023 - 07:36

363

363

Fierce Pharma

JANUARY 3, 2024

Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)

Sales 321

Sales Biopharma Leads Marketing 321

Fierce Pharma

FEBRUARY 14, 2023

Pfizer CEO's texts with European Commission chief trigger new NYT lawsuit kdunleavy Tue, 02/14/2023 - 10:29

364

364

Fierce Pharma

APRIL 19, 2023

Goodbye, original COVID-19 vaccines: FDA updates shot guidance, pulls monovalent authorizations zbecker Wed, 04/19/2023 - 11:04

FDA 364

FDA 364

Fierce Pharma

FEBRUARY 28, 2024

As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024. | As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024.

298

298

Fierce Pharma

JANUARY 26, 2023

BMS settles lawsuit with two fired employees who refused COVID vaccines kdunleavy Thu, 01/26/2023 - 14:30

361

361

Fierce Pharma

MARCH 1, 2023

Pfizer, Viatris and more must face 'overarching conspiracy' claims in generic price-fixing suit aliu Wed, 03/01/2023 - 10:03

364

364

Fierce Pharma

FEBRUARY 24, 2023

Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license esagonowsky Fri, 02/24/2023 - 09:18

Government 364

Government 364

Fierce Pharma

MAY 19, 2023

Krystal's Vyjuvek becomes first topical gene therapy with FDA nod to treat rare skin disease zbecker Fri, 05/19/2023 - 16:25

FDA 363

FDA 363

Fierce Pharma

FEBRUARY 20, 2024

AstraZeneca CEO Pascal Soriot’s compensation package makes him the current top contender for 2023’s highest-paid pharma CEO in Europe. Still, as in years past, not everyone is pleased with Soriot’s 2023 windfall. AstraZeneca, having surpassed its long-term $45 billion revenue goal last year, has handsomely rewarded its chief executive.

Pharma 299

Pharma 299

Fierce Pharma

MAY 16, 2024

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.

Biopharma 312

Biopharma Pharma 312

Fierce Pharma

MAY 21, 2024

A decade ago, with AstraZeneca in decline and some investors urging the drugmaker to sell out to Pfizer, new CEO Pascal Soriot presented an audacious plan to hike revenue to $45 billion by 2023. After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again.

306

306

Fierce Pharma

APRIL 21, 2023

In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk's Wegovy aliu Fri, 04/21/2023 - 22:35

363

363

Fierce Pharma

FEBRUARY 3, 2023

J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries mbayer Fri, 02/03/2023 - 09:29

Pharma 363

Pharma 363

Fierce Pharma

JANUARY 25, 2023

Merck's Keytruda dealt another blow in prostate cancer but readies new challenge to AZ's Imfinzi aliu Wed, 01/25/2023 - 10:17

361

361

Fierce Pharma

FEBRUARY 1, 2024

After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024. After GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024.

296

296

Fierce Pharma

FEBRUARY 28, 2023

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv kdunleavy Tue, 02/28/2023 - 18:55

FDA 351

FDA 351

Fierce Pharma

FEBRUARY 15, 2023

GSK was warned repeatedly about Zantac impurity but played down risks: Bloomberg esagonowsky Wed, 02/15/2023 - 09:02

352

352

Fierce Pharma

APRIL 3, 2023

After Johnson & Johnson loses again in bankruptcy case, it's game on for talc lawsuits kdunleavy Mon, 04/03/2023 - 06:44

351

351

Fierce Pharma

APRIL 4, 2023

talc settlement offer esagonowsky Tue, 04/04/2023 - 17:40 J&J opens its wallet with whopping $8.9B

347

347